Clinical Trial Update: This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update outlines a Phase 2/Phase 3 study evaluating the safety, target engagement, and preliminary efficacy of galunisertib (TGF-βR1/ALK5 inh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Galunisertib (galunisertib)
• Nerandomilast

Snippet

Sponsor: Gipfel Life Sciences GmbH | Conditions: ALS (Amyotrophic Lateral Sclerosis) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING